Emactuzumab

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

Emactuzumab (RG 7155) 是一种特异性单克隆抗体，可抑制集落刺激因子 1 受体 (CSF1R) 的激活。Emactuzumab 对 CSF-1R 具有高亲和力，Ki 值为 0.2 nM，可阻断 CSF-1R 二聚化。Emactuzumab 可用于多种疾病的研究，如弥漫型腱鞘巨细胞瘤（dt-GCT）。

Emactuzumab(RG 7155) is a specific monoclonal antibody that inhibits colonystimulating factor 1 receptor (CSF1R) activation. Emactuzumab has high affinity for CSF-1R with Ki value of 0.2 nM to blocks CSF-1R dimerization. Emactuzumab can be used for the research of several diseases, such as diffuse-type tenosynovial giant cell tumour (dt-GCT) .

Emactuzumab (RG 7155) binds to human and cynomolgus CSF-1R with high affinity (Kd = 0.2 nM) to blocks CSF-1R dimerization.RG7155 (0-10 μg/mL, 7 days) potently inhibited the viability of CSF-1-differentiated macrophages with an IC50 of 0.3 nM by inducing cell death.RG7155 (30 μg/mL, 6 days) induces cell death of in vitro-differentiated human M2-like macrophages.Cell Viability Assay Cell Line:CSF-1 and/or GM-CSF Macrophages Concentration:0-10 μg/mL Incubation Time:7 days Result:Resulted cell death of CSF-1-differentiated macrophages.

Emactuzumab(RG 7155) (i.v.; 0.1、1、10、30 and 100 mg/kg; once) increases CSF-1 concentration in nonhuman primates’ peripheral blood.RG7155 (i.v.; 0, 30, and 100 mg/kg; once weekly; for 2 weeks) depletes CSF-1R+CD163+ macrophages in vivo.Animal Model:cynomolgus monkeys Macaca fascicularis Dosage:0.1, 1, 10, 30 and 100 mg/kg (male cynomolgus monkeys)0, 30, and 100 mg/kg (male and female cynomolgus) Administration:i.v., once (male cynomolgus monkeys) i.v., once weekly, for 2 weeks(male and female cynomolgus) Result:Increased CSF-1 concentration in serum.Efficiently reduced CSF-1R and CD68+163+ macrophages in the liver (Kupffer cells) and colon of cynomologus monkeys.

——

Tyrosine Kinase

CSF1R

c-Fms | TAM Receptor

——

——

1448221-67-7

——

>98% (HPLC)

——

——

——

(-20℃)

With Ice Pack

≥ 2 years